Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.

Détails

ID Serval
serval:BIB_185CF6E88C32
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.
Périodique
Virchows Archiv
Auteur(s)
Klöppel G., La Rosa S.
ISSN
1432-2307 (Electronic)
ISSN-L
0945-6317
Statut éditorial
Publié
Date de publication
03/2018
Peer-reviewed
Oui
Volume
472
Numéro
3
Pages
341-349
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
In 1983, a monoclonal antibody, Ki67, was generated, that labeled the nuclei of proliferating non-neoplastic and neoplastic cells. The name Ki67 derived from the city of Kiel (Ki) where the antibody was produced in the university department of pathology and refers to the number of the original clone (67). Systematic assessment of the proliferative activity of tumors using Ki67 started in the 1990s, when Ki67, which only worked on frozen tissue, was complemented by the antibody MIB-1 that also worked in formalin-fixed tissues. Pancreatic neuroendocrine neoplasms (PanNENs) were the first endocrine tumors whose proliferative activity was assessed with Ki67. This approach was so successful that Ki67 was included as prognostic marker in the 2000 and 2004 WHO classifications of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). In 2010, the WHO classification of GEP-NENs introduced a three-tiered grading, originally proposed by ENETS in 2006 that was mainly based on the Ki67 index. As it has subsequently been shown that the Ki67 index is the most reliable factor in the prognostic evaluation of GEP-NENs, especially of PanNENs, the 2017 WHO classification of PanNENs requires its use and strongly recommends exact assessment of the proportion Ki67-labeled cells as basis for the calculation of the Ki67 index. Problems in assessing the Ki67 index include intertumoral and intratumoral staining heterogeneity and counting methods. Despite such problems, the Ki67 index has emerged as indispensable for the prognostic and therapeutic stratification of the majority of GEP-NENs and can barely be replaced by counting mitoses. In future, however, it can be anticipated that the Ki67 cut-offs experience refinement in relation to the type of tumor, its location, and its response to therapy. It is also possible that the prognostic risk of an individual tumor is calculated for each Ki67 unit and not for an "a priori" fixed Ki67 class.

Mots-clé
Biomarkers, Tumor/metabolism, Humans, Ki-67 Antigen/metabolism, Neuroendocrine Tumors/diagnosis, Neuroendocrine Tumors/metabolism, Neuroendocrine Tumors/pathology, Pancreatic Neoplasms/diagnosis, Pancreatic Neoplasms/metabolism, Pancreatic Neoplasms/pathology, Prognosis, Stomach Neoplasms/diagnosis, Stomach Neoplasms/metabolism, Stomach Neoplasms/pathology, Assessment, History, Intestine, Ki67, Neuroendocrine neoplasms, Pancreas, Prognostic marker, Stomach
Pubmed
Web of science
Création de la notice
16/11/2017 21:06
Dernière modification de la notice
20/08/2019 12:48
Données d'usage